An experimental cancer vaccine that boosts the immune system’s ability to fight cancers could work in tandem with other cancer therapies to fight aggressive tumours, scientists have reported….
An experimental cancer vaccine that boosts the immune system’s ability to fight cancers could work in tandem with other cancer therapies to fight aggressive tumours, scientists have reported.
The researchers demonstrated that adding a molecule called Diprovocim to a vaccine can draw cancer-fighting cells to tumour sites.
The vaccine also prompts the immune system to fight tumour cells should they ever return, a capability that could prevent cancer recurrence.
The mice were then split into three group: eight received the cancer vaccine, eight received the cancer vaccine plus Diprovocim, and eight received the cancer vaccine plus an alternative adjuvant called alum.
The researchers observed a 100 percent survival rate over 54 days in the mice given the cancer vaccine and Diprovocim.
Prof Boger and Dr Beutler have acknowledged a financial interest in Tollbridge Therapeutics, LLC, which has licensed the patent for Diprovocim. »
